Tianeptine Interactions: Alcohol, Caffeine, Food and Other Compounds

How "Interaction" Is Defined in the Published Tianeptine Literature

Questions about combining tianeptine with another substance usually collapse three separate research questions into one. The first is pharmacokinetic: does one compound change the absorption, distribution, metabolism or clearance of the other? The second is pharmacodynamic: do the two compounds act on overlapping receptor systems or downstream signalling pathways? The third is observational: what outcomes were recorded when both substances were present in the same person, typically in case reports, poison-centre records or surveillance datasets. The tianeptine literature addresses these three questions very unevenly, and most of the combinations people ask about have never been the subject of a dedicated interaction study at all.

Where dedicated interaction studies are absent, this page says so plainly rather than filling the gap with inference presented as fact. Where inference is discussed, it is labelled as mechanistic reasoning. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decisions relating to health or medication.

Tianeptine and Alcohol: What the Literature Covers

The verified literature reviewed here contains no controlled human trial and no animal study that co-administered tianeptine and ethanol and measured a pharmacokinetic or behavioural interaction. That absence is the finding. Claims about how the pairing behaves do not rest on a published co-administration experiment.

Mechanistic reasoning (labelled as such, not interaction evidence)

The reasoning researchers apply in the absence of direct data draws on the glutamatergic systems both substances touch. In a rodent model, researchers reported that CaMKII\u03b1\u2013GluA1 activity underlies vulnerability to adolescent binge alcohol drinking, implicating AMPA-receptor trafficking in alcohol-related behaviour (https://pubmed.ncbi.nlm.nih.gov/26247621/). That study did not administer tianeptine and did not test any antidepressant; it is cited here only because tianeptine is frequently discussed in glutamatergic and AMPA-related terms, and because that shared vocabulary is the entire basis for the popular assumption of an interaction. Shared pathway vocabulary is not a measured interaction.

A second strand of reasoning concerns tianeptine's opioid-receptor activity. Researchers examined the discriminative stimulus properties of tianeptine in animals, work that situates the compound within opioid-related behavioural pharmacology rather than within classical antidepressant pharmacology alone (https://pubmed.ncbi.nlm.nih.gov/16292591/). Because central depressant effects are the standard concern raised whenever an opioid-active compound and ethanol appear together, this receptor profile is the pharmacological reason the question is asked \u2014 but again, no study in this set combined the two.

Tianeptine and Caffeine or Stimulants

No study in the verified set examined tianeptine with caffeine, and no pharmacokinetic drug\u2013drug interaction trial pairing tianeptine with a stimulant appears in this literature. The adjacent stimulant pharmacology evidence that does exist addressed an entirely different question: a practitioner review and systematic review with meta-analysis evaluated pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder, and tianeptine was not among the compounds under review (https://pubmed.ncbi.nlm.nih.gov/32845025/). Citing it here is a way of showing where the boundary of the evidence sits, not of implying a transferable result.

The mechanistic argument commonly made \u2014 that adenosine-receptor antagonism and \u03bc-opioid receptor activity are separate systems that might oppose one another subjectively \u2014 is reasoning, not data. Nothing in the verified literature measured alertness, heart rate, plasma levels or any other endpoint in people or animals given both compounds.

Food, Fasting and Absorption

The verified literature contains no food-effect study for tianeptine: no fed-versus-fasted crossover, no measurement of how a meal shifted peak concentration or total exposure. Readers encountering confident statements about taking tianeptine \"with food\" or \"on an empty stomach\" should note that this set of papers does not contain the experiment that would support such a statement.

What the literature does provide is analytical chemistry that bears on how tianeptine is measured and characterised in the first place. In a 2025 analytical study, researchers reported enantiomeric separations, structural assignment and biological interactions for tianeptine, work concerned with distinguishing the compound's stereoisomers and characterising their interactions at the molecular level (https://pubmed.ncbi.nlm.nih.gov/40339337/). The word \"interactions\" in that study refers to molecular-level binding characterisation, not to drug\u2013drug or drug\u2013food interaction testing \u2014 a distinction that is easy to lose when abstracts are skimmed.

Tianeptine With Antidepressants: The One Combination Study

The clearest combination evidence in this set involves SSRIs. Researchers investigated tianeptine combination treatment in patients with partial response or non-response to selective serotonin re-uptake inhibitor monotherapy, making this the one clinical context in the verified literature in which tianeptine was deliberately added to another psychotropic and outcomes were followed (https://pubmed.ncbi.nlm.nih.gov/23683152/). The study was conducted in a clinical population under clinical supervision; it described a treatment strategy examined by clinicians and reported in a psychiatry journal, and it does not generalise to unsupervised combinations of tianeptine with other substances.

Opioid-Receptor Pharmacology and Why Combination Questions Arise

Much of the interest in tianeptine combinations traces back to its activity at \u03bc-opioid receptors. Researchers characterised the discriminative stimulus properties of tianeptine in animal behavioural pharmacology, the experimental approach used to ask what internal state a drug resembles (https://pubmed.ncbi.nlm.nih.gov/16292591/). Separately, a neuropharmacology study examined how the compound SR-17018 activated \u03bc receptors through a distinctive mechanism, illustrating that \u03bc-receptor activation is not a single uniform event and that different ligands engage the receptor differently (https://pubmed.ncbi.nlm.nih.gov/39067665/). That study did not involve tianeptine; it is included as background on why \"acts at \u03bc receptors\" is an incomplete description of any compound's behaviour.

Plasticity signalling as background

Tianeptine is also discussed in the neuroplasticity literature. A Novartis Foundation symposium review addressed neurotrophins and cytokines in neuronal plasticity, covering the signalling systems commonly invoked in explanations of antidepressant action (https://pubmed.ncbi.nlm.nih.gov/18497106/). This is mechanistic background, not interaction evidence: no combination with alcohol, caffeine or food was tested in that work.

Route of Administration and Overdose Contexts: What Studies Report

The most concrete human data in this set come from toxicology rather than from interaction pharmacology. A case report in the Journal of Analytical Toxicology described acute toxicity following intravenous use of tianeptine, documenting a route of administration far removed from the oral tablet formulations studied in psychiatry (https://pubmed.ncbi.nlm.nih.gov/28541419/). A forensic science report documented a fatal intoxication involving tianeptine marketed as Stablon (https://pubmed.ncbi.nlm.nih.gov/17630235/).

At the population level, researchers analysed tianeptine-involved emergency department visits, fatal overdoses and substance seizures in Tennessee across 2021 to 2023, reporting on all three data streams within a single state surveillance analysis (https://pubmed.ncbi.nlm.nih.gov/39258110/). Surveillance datasets of this kind describe what was recorded in real-world exposures; they are not designed to isolate the contribution of any single co-ingested substance, and they do not establish which combination, if any, drove a given outcome.

Evidence Status by Combination

Why Case Reports and Surveillance Data Cannot Answer Interaction Questions

Case reports describe a single exposure in a single person, usually because the outcome was unusual enough to publish; the intravenous acute toxicity report and the fatal intoxication report are both of this type (https://pubmed.ncbi.nlm.nih.gov/28541419/, https://pubmed.ncbi.nlm.nih.gov/17630235/). Surveillance analyses such as the Tennessee dataset aggregate recorded events across a jurisdiction and time window and describe trends rather than causal mechanisms (https://pubmed.ncbi.nlm.nih.gov/39258110/). Neither design randomises exposure, controls co-ingestants, or measures plasma concentrations under standardised conditions, which is what a pharmacokinetic interaction study requires.

Limitations of This Evidence Base

• No dedicated interaction trials. For alcohol, caffeine and food, the verified literature contains no co-administration experiment in humans or animals; the gap is stated rather than filled by extrapolation.
• Mechanism is not outcome. Receptor-level and pathway-level findings, including \u03bc-receptor mechanism work (https://pubmed.ncbi.nlm.nih.gov/39067665/) and neurotrophin\u2013cytokine plasticity signalling (https://pubmed.ncbi.nlm.nih.gov/18497106/), describe systems, not combination outcomes.
• Clinical versus non-clinical settings differ. The SSRI combination work occurred in a supervised clinical population (https://pubmed.ncbi.nlm.nih.gov/23683152/), whereas the toxicology reports describe exposures well outside that context (https://pubmed.ncbi.nlm.nih.gov/39258110/).
• Stereochemistry is still being characterised. Researchers reported enantiomeric separation and structural assignment for tianeptine only recently, which complicates comparisons across older studies (https://pubmed.ncbi.nlm.nih.gov/40339337/).

References

• Discriminative stimulus properties of tianeptine (Psychopharmacology, 2006)
• Fatal intoxication with tianeptine (Stablon) (Forensic Science International, 2007)
• Neurotrophins and cytokines in neuronal plasticity (Novartis Foundation Symposium, 2008)
• Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy (Psychiatry and Clinical Neurosciences, 2013)
• CaMKII\u03b1-GluA1 Activity Underlies Vulnerability to Adolescent Binge Alcohol Drinking (Alcoholism, Clinical and Experimental Research, 2015)
• Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine (Journal of Analytical Toxicology, 2017)
• Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis (Journal of Child Psychology and Psychiatry, 2021)
• Activation of \u03bc receptors by SR-17018 through a distinctive mechanism (Neuropharmacology, 2024)
• Tianeptine-involved emergency department visits, fatal overdoses, and substance seizures in Tennessee, 2021-2023 (Drug and Alcohol Dependence Reports, 2024)
• Tianeptine: enantiomeric separations, structural assignment, and biological interactions (Talanta, 2025)